PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 05: MARKET SIZING • Market definition • Market sizing 2017 • Market size and forecast 2017-2022 PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: PIPELINE LANDSCAPE PART 08: MARKET SEGMENTATION BY APPLICATION • Segmentation by application • Comparison by application • Drugs – Market size and forecast 2017-2022 • Vaccines – Market size and forecast 2017-2022 • Market opportunity by application PART 09: CUSTOMER LANDSCAPE PART 10: REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • Americas – Market size and forecast 2017-2022 • EMEA – Market size and forecast 2017-2022 • APAC – Market size and forecast 2017-2022 • Market opportunity PART 11: DECISION FRAMEWORK PART 12: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 13: MARKET TRENDS • Strategic alliances • Strong pipeline • New technological advancements PART 14: VENDOR LANDSCAPE • Overview • Landscape disruption PART 15: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Bristol-Myers Squibb • F. Hoffmann-La Roche • Gilead • GlaxoSmithKline • Merck Sharp & Dohme PART 16: APPENDIX • List of abbreviations     Exhibit 01: Parent market Exhibit 02: Global infectious disease treatment market segmentation Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2017 Exhibit 07: Validation techniques employed for market sizing 2017 Exhibit 08: Global hepatitis B therapeutics market – Market size and forecast 2017-2022 ($ mn) Exhibit 09: Global hepatitis B therapeutics market – Year-over-year growth 2018-2022 (%) Exhibit 10: Five forces analysis 2017 Exhibit 11: Five forces analysis 2022 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 20 Exhibit 18: Pipeline landscape by development phase Exhibit 19: Global hepatitis B therapeutics pipeline: Overview Exhibit 20: Application – Market share 2017-2022 (%) Exhibit 21: Comparison by application Exhibit 22: Drugs – Market size and forecast 2017-2022 ($ mn) Exhibit 23: Drugs – Year-over-year growth 2018-2022 (%) Exhibit 24: Vaccines – Market size and forecast 2017-2022 ($ mn) Exhibit 25: Vaccines – Year-over-year growth 2018-2022 (%) Exhibit 26: Market opportunity by application Exhibit 27: Customer landscape Exhibit 28: Global – Market share by geography 2017-2022 (%) Exhibit 29: Regional comparison Exhibit 30: Americas – Market size and forecast 2017-2022 ($ mn) Exhibit 31: Americas – Year-over-year growth 2018-2022 (%) Exhibit 32: Top 3 countries in Americas Exhibit 33: EMEA – Market size and forecast 2017-2022 ($ mn) Exhibit 34: EMEA – Year-over-year growth 2018-2022 (%) Exhibit 35: Top 3 countries in EMEA Exhibit 36: APAC – Market size and forecast 2017-2022 ($ mn) Exhibit 37: APAC – Year-over-year growth 2018-2022 (%) Exhibit 38: Top 3 countries in APAC Exhibit 39: Market opportunity Exhibit 40: Vendor landscape Exhibit 41: Landscape disruption Exhibit 42: Vendors covered Exhibit 43: Vendor classification Exhibit 44: Market positioning of vendors Exhibit 45: Bristol-Myers Squibb – Overview Exhibit 46: Bristol-Myers Squibb – Business segments Exhibit 47: Bristol-Myers Squibb – Organizational developments Exhibit 48: Bristol-Myers Squibb – Geographic focus Exhibit 49: Bristol-Myers Squibb – Key offerings Exhibit 50: Bristol-Myers Squibb – Key customers Exhibit 51: F. Hoffmann-La Roche – Overview Exhibit 52: F. Hoffmann-La Roche – Business segments Exhibit 53: F. Hoffmann-La Roche – Organizational developments Exhibit 54: F. Hoffmann-La Roche – Geographic focus Exhibit 55: F. Hoffmann-La Roche – Segment focus Exhibit 56: F. Hoffmann-La Roche – Key offerings Exhibit 57: F. Hoffmann-La Roche – Key customers Exhibit 58: Gilead – Overview Exhibit 59: Gilead – Business segments Exhibit 60: Gilead – Organizational developments Exhibit 61: Gilead – Geographic focus Exhibit 62: Gilead – Key offerings Exhibit 63: Gilead – Key customers Exhibit 64: GlaxoSmithKline – Overview Exhibit 65: GlaxoSmithKline – Business segments Exhibit 66: GlaxoSmithKline – Organizational developments Exhibit 67: GlaxoSmithKline – Geographic focus Exhibit 68: GlaxoSmithKline – Segment focus Exhibit 69: GlaxoSmithKline – Key offerings Exhibit 70: GlaxoSmithKline – Key customers Exhibit 71: Merck Sharp & Dohme – Overview Exhibit 72: Merck Sharp & Dohme – Business segments Exhibit 73: Merck Sharp & Dohme – Organizational developments Exhibit 74: Merck Sharp & Dohme – Geographic focus Exhibit 75: Merck Sharp & Dohme – Segment focus Exhibit 76: Merck Sharp & Dohme – Key offerings Exhibit 77: Merck Sharp & Dohme – Key customers

Bristol-Myers Squibb F. Hoffmann-La Roche Gilead GlaxoSmithKline and Merck Sharp & Dohme